FDA Fast-Tracks Prevail’s PROO1 for Parkinson’s

Prevail Therapeutics (NASDAQ:PRVL) is up 12% premarket on light volume on the heels of the FDA designating gene therapy PR001 for Fast Track review for the treatment of GBA1 mutation-positive Parkinson’s disease patients.

Dosing in a Phase 1/2 study should commence in H2.

https://seekingalpha.com/news/3476161-fda-fast-tracks-prevails-proo1-parkinsons-shares-12-percent-premarket